Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany-Reference-Cited by-同舟云学术

Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany

Published:2015-11-14 Issue:10 Volume:61 Page:3061-3071
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Dig Dis Sci

Author:

Petersen Jörg,Heyne Renate,Mauss Stefan,Schlaak Jörg,Schiffelholz Willibald,Eisenbach Christoph,Hartmann Heinz,Wiese Manfred,Boeker Klaus,Loehr Hanns-Friedrich,John Christine,Leuschner Maria,Trautwein Christian,Felten Gisela,Trein Andreas,Krause Wolfgang,Ruppert Susanne,Warger Tobias,Hueppe Dietrich

Funder

Gilead Sciences GmbH

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Physiology

Link

http://link.springer.com/article/10.1007/s10620-015-3960-x/fulltext.html

Reference25 articles.

1. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455.

2. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–475.

3. Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014;59:434–442.